12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Spiriva Respimat tiotropium: Phase II data

A double-blind, crossover, international Phase II trial in 105 patients aged 12-17 with symptomatic, moderate persistent asthma who were receiving inhaled corticosteroids (ICS) with or without long-acting beta agonists (LABA) or leukotriene receptor antagonists showed that once-daily 5 µg Spiriva Respimat significantly improved lung function from baseline to week 4 as measured by peak FEV1 from 0-3 hours post-dose, the primary endpoint, vs. placebo (0.602...

Read the full 303 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >